MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma
对于套细胞淋巴瘤,以微小残留病灶(MRD)为导向的初始治疗方案为阿卡替尼联合来那度胺加利妥昔单抗或奥妥珠单抗。
期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2025017760
Ruan, Jia; Bond, David A; Shah, Bijal; Allan, John N; Rutherford, Sarah C; Gribbin, Caitlin; Chen, Zhengming; Bhinder, Bhavneet; Tam, Wayne; Rossi, Davide; Xiang, Jenny; Hobbie, Brittany; Harbhajan, Melinda; Sahni, Tejasvi K; Chen, Gui Z; Sigouros, Michael; Inghirami, Giorgio; Chen-Kiang, Selina; Elemento, Olivier; Maddocks, Kami; Leonard, John P; Martin, Peter